Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis
A Phase 2 Assessment of Humacyte's Human Acellular Vessel in Patients Needing Vascular Access for Dialysis
Sponsor: Humacyte, Inc.
A PHASE2 clinical study on End Stage Renal Disease and Hemodialysis, this trial is completed. The trial is conducted by Humacyte, Inc. and has accumulated 12 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Jan 2022 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2019 — Mar 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Humacyte, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .